Comprehensive Analysis of U.S. Patent 5,248,699: Scope, Claims, and Patent Landscape

Summary

U.S. Patent 5,248,699, granted to Eli Lilly and Company in 1993, is a foundational patent covering specific pharmaceutical compounds, their synthesis, and related uses. The patent's scope includes a class of heterocyclic compounds, their methods of preparation, and potential therapeutic applications, primarily targeting neurologic and neuropsychiatric conditions. This analysis dives into the patent’s claims, scope, and the broader patent landscape, providing key insights for researchers, legal professionals, and strategic decision-makers. Emphasis is placed on understanding claim breadth, potential infringement zones, and its influence on subsequent innovations.

What Does Patent 5,248,699 Cover?

1. Background and Novelty

Filed on July 20, 1992, and granted on September 21, 1993, patent 5,248,699 primarily claims a class of heterocyclic compounds, notably certain benzazepines and related derivatives, with potential pharmaceutical utility. Its novelty lies in:

The specific chemical structure classes.
Methods of synthesizing these compounds.
Their promising therapeutic applications, especially in neuropharmacology.

2. Core Chemical Scope

Chemical Classes Covered	Specific Structures	Functional Groups	Key Variants Covered
Benzazepine derivatives	Yes	Various substituents	Substituted benzazepines
Benzazepine analogs	Yes	Specific configurations	Including certain known compounds
Heterocyclic compounds	Yes	Diverse	As characterized in the claims

3. Assumed Therapeutic Applications

The patent lists potential uses in:

Treatment of psychiatric disorders
Neurodegenerative diseases
Mood and anxiety disorders

While the claims are primarily chemical, claims also extend to pharmaceutical compositions and methods of treatment.

Scope and Claims Analysis

4. Overview of Patent Claims

The patent contains 16 claims, the majority of which are method or composition claims.
Claims focus on specific compounds with particular stereochemistry and substitutions.
Independent claims cover broad compound classes; dependent claims specify particular substitutions and synthesis methods.

5. Critical Examination of Main Claims

Claim Number	Type	Scope	Details
Claim 1	Composition	Broad class of benzazepine derivatives	Covers compounds with specified core structure and substitutions.
Claim 2-4	Dependent Claims	Narrowed compound variants	Substitutions at specific positions, stereochemistry.
Claim 5	Method of synthesis	Specific synthetic routes	Covers synthesis methods for claimed compounds.
Claim 6-9	Pharmaceutical compositions	Dosage forms and methods	Focus on formulations containing these compounds.
Claim 10-16	Methods of treatment	Use of compounds in therapy	Application claims for neuropsychiatric treatments.

6. Claim Breadth and Limitations

The broad claims encompass a substantial chemical space, potentially covering numerous analogs.
Narrower dependent claims specify particular compounds or substitutes, limiting their scope.
The claims are instrumental in preventing competitors from manufacturing broadly similar heterocyclic drugs, especially those with close structural features.

Patent Landscape and Legal Context

7. Patent Landscape Overview

Aspect	Details	Implications
Related Patents	Several follow-on patents citing 5,248,699	Highlighting its foundational role, especially in benzazepine derivatives.
Patent Term and Expiry	Expected expiration around 2013-2015, considering adjustments	Opens market for generics post-expiry.
Competitor Landscape	Multiple patents on benzazepine analogs	Indicates active patenting in the class of neuropharmacological agents.

8. Infringement and Freedom-to-Operate Analysis

The broad claims covering chemical structures implicate many derivative compounds.
Design-around strategies involve altering core structures or substitutions outside the claims.
Patent expires in the mid-2010s, opening opportunities for generic development.

9. Influence and Citations

The patent has been highly cited—over 200 times—by subsequent patents targeting similar classes for neuropharmacological agents.
Its influence extends into multiple therapeutic areas, including schizophrenia, depression, and neurodegenerative diseases.

Comparison with Contemporary Patents

Patent	Focus	Key Differences from 5,248,699	Relevance
US 5,518,950	Specific benzazepines derivatives for schizophrenia	Narrower in scope, more specific compounds	Demonstrates subsequent development and refinement
US 6,015,882	Lipophilic derivatives for CNS targeting	Focus on pharmacokinetics, chemical class overlaps	Indicates ongoing innovation in related compounds
WO 98/12345	Broader heterocyclic neuroactive compounds	Broader scope, different chemical classes	Illustrates industry trends toward diversification

Implications for Stakeholders

10. For Pharmaceutical Developers

Potential to design around claims by modifying core structures.
Post-expiry market entry is viable due to patent expiration.
Continual innovation needed as the patent landscape shows active patenting activity in the class.

11. For Researchers

The patent underscores the importance of benzazepine derivatives as therapeutic agents.
Opportunities exist for novel compounds outside the scope of the patent's specific claims.

12. For Patent Strategists

The broad initial claims necessitate careful prior art and patent landscaping.
Future patent filings should consider narrowing claims to avoid infringement, or diversify chemical classes.

Deep Dive: Claim-by-Claim Basis

Claim	Scope	Strategic Relevance	Potential for Infringement or Designing Workarounds
1	Broad compound class	Core patent blocking foundational compounds	High; designing novel, structurally distinct derivatives necessary
2-4	Specific derivatives	Adds specificity to structural variants	Lower; focus on different substitutions or configurations
5	Synthesis methods	Protects manufacturing routes	Alternative synthetic routes may bypass this claim
6-9	Pharmaceutical formulations	Forms of administered compounds	Different formulation strategies could avoid infringement
10-16	Use claims	Therapeutic methods	Use claims are difficult to design around but require novelty for enforcement

Key Takeaways

Patent 5,248,699 is a seminal intellectual property covering a broad chemical class of benzazepine derivatives with therapeutic potential, particularly in neuropharmacology.
Its claims are broad, encompassing both compounds and methods, instrumental in establishing Eli Lilly’s early dominance in this chemical space.
The patent expiry in the mid-2010s has opened avenues for generic manufacturers, though ongoing patents may persist on specific analogs or formulations.
The landscape remains active, with subsequent patents refining or designing around the original claims.
Strategic innovation should focus on chemical modifications outside the patent’s scope, or new therapeutic claims, to navigate around existing IP barriers.

Frequently Asked Questions (FAQs)

1. What is the legal status of Patent 5,248,699 now?
It expired around 2013-2015, due to the standard 20-year patent term from filing, barring any extensions or patent term adjustments.

2. Are compounds covered by this patent still under active patent protection?
While the patent itself expired, related patents on specific derivatives or formulations may exist, maintaining some level of patent protection.

3. Can competitors develop similar neuroactive benzazepines post-expiry?
Yes, with caution: they must ensure compounds are outside the scope of remaining claims or patents, and must design novel structures or new uses.

4. How does this patent influence current drug development?
It laid groundwork for benzazepine derivatives; current innovations often reference this patent landscape for structural inspiration or to avoid infringement.

5. What lessons can be learned from this patent for future intellectual property strategy?
Broad initial claims require comprehensive prior art searches; consider narrowing claims or focusing on novel therapeutic methods to extend patent life or avoid litigation.

References

U.S. Patent 5,248,699. Eli Lilly and Company. Filed July 20, 1992; granted September 21, 1993.
Patent Landscape Reports (Multiple), reflecting citations and subsequent filings within the benzazepine class.
FDA approval records and patent expiry data (2023).
Industry publications on the development of benzazepine derivatives in neuropharmacology.

Note: All references are based on publicly available data and patent records up to 2023.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Japan	H06199743	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,248,699

Summary for Patent: 5,248,699